Press & News

People are different and so is their cancer, patients should be treated individually.

New The power of precision, For Every Oncologist, Today

With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.

Latest News

Dr. Raphael Gruber joins 2cureX as new Medical Director

Latest press and news

May 17

IR

Three IndiTreat® posters have been accepted at ESMO-GI 2022

May 12

IR

Regulatory

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

May 12

IR

Regulatory

Swedish

2cureX AB nominerar Dr. Michael Schaefer till styrelsen

May 11

IR

IGNITE update – Eight hospitals have been enrolled in the program

May 9

IR

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

May 6

IR

Regulatory

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

May 6

IR

Regulatory

Swedish

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

May 5

IR

Redeye research interview with 2cureX CEO, Fernando Andreu